Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm
01:34pm, Tuesday, 11'th Jul 2023
The European Medicines Agency said Tuesday it's reviewing data on the risk of suicidal thoughts and self-harm stemming from the use of the new medicines called GLP-1 receptor agonists, that are used t
DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership
10:22am, Tuesday, 11'th Jul 2023
Ginkgo Bioworks (NYSE: DNA ) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk (NYSE: NVO ). These two companies have been working together on the deve
The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
09:59pm, Monday, 10'th Jul 2023
Novo Nordisk, a global healthcare company, is expected to see significant growth due to its focus on Anti-Obesity Medication and novel GLP-1 therapies, particularly semaglutide-based medications Ozemp
Ozempic faces review over concerns it may trigger suicidal thoughts
03:57pm, Monday, 10'th Jul 2023
Rapid-weight-loss shot Ozempic, which is manufactured by pharmaceutical company Novo Nordisk, is being probed by European drug-safety regulators after two users reported thoughts of suicide.
EU Investigates Ozempic Maker After Reports Of Suicidal Thoughts
01:58pm, Monday, 10'th Jul 2023
The Danish pharma giant finds itself under scrutiny once again- this time, from European regulators.
Ozempic and other weight loss drugs are 'upending the entire idea' of weight loss, reporter says
01:10pm, Monday, 10'th Jul 2023
Nathan Bomey, Axios Business Reporter and Co-author of the Axios Closer Newsletter, joins Yahoo Finance Live anchors Julie Hyman and Brad Smith to discuss the popularity of prescription weight loss dr
European regulator to review weight-loss drugs following reports of suicidal thoughts
10:21am, Monday, 10'th Jul 2023
Danish firm Novo Nordisk says "patient safety is a top priority" following reports.
Wegovy maker Novo Nordisk sues Florida pharmacies over copycat drugs
05:21pm, Thursday, 06'th Jul 2023
Novo Nordisk on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in the Danish drugmaker's weight loss and diabetes drugs
Novo Nordisk spent $11 million on Ozempic promotion
03:08pm, Thursday, 06'th Jul 2023
Novo Nordisk spent $11 million on food and travel for doctors to promote weight loss and type 2 diabetes drug Ozempic. Yahoo Finance Healthcare Reporter Anjalee Khemlani discusses Novo Nordisk's lobby
Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher
09:15am, Thursday, 06'th Jul 2023
It has been hugely popular for weight loss even though it's not approved for that use. The drug's potential could go far beyond just weight loss and diabetes, however.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:38am, Thursday, 29'th Jun 2023
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Medicare coverage of weight-loss drugs? Don't count on it, analysts say.
08:32am, Thursday, 29'th Jun 2023
Investors should not bank on Medicare covering the powerful new weight-loss drugs from Eli Lilly & Co. LLY, -1.25%, Novo Nordisk NVO, +0.52% and other drugmakers any time soon, Beacon Policy Advisors
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
11:18am, Tuesday, 27'th Jun 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Factbox: Weight-loss drugs: the next gold rush
10:56am, Tuesday, 27'th Jun 2023
Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.
New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studies
07:40am, Tuesday, 27'th Jun 2023
Dr. Angela Fitch, Knownwell chief medical officer and president of Obesity Medicine Association, joins 'Squawk Box' to discuss the advances in weight-loss drugs, what it means for the obesity epidemic
